Lakewood-Amedex Biotherapeutics Takes a Bold Step with Nasdaq Listing

On April 23, 2026, Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT), a promising clinical-stage biotechnology firm, celebrated the commencement of trading its shares on the Nasdaq Capital Market. This pivotal moment marks a significant milestone in the company's journey, especially in the realm of developing innovative antimicrobial therapies. The company specializes in a new class of fast-acting, broad-spectrum antimicrobials known as the Bisphosphocin® class, aimed at combatting various infectious diseases.

A New Chapter for Lakewood-Amedex

In a statement following the public trading announcement, Dr. Doug Manion, Chairman of the Board, expressed his excitement, stating, "This listing is a notable achievement marking a new chapter for our company enabling the accelerated development of our Bisphosphocin® class of compounds, including our lead product, Nu-3, as a potential treatment for infected diabetic foot ulcers (iDFU)." This reflects a strong commitment to addressing critical health challenges faced by patients, particularly those suffering from diabetes.

With nearly 40 million individuals in the U.S. living with diabetes, the statistics are alarming: one-third will develop a diabetic foot ulcer in their lifetime, and approximately half of those will experience infections. Considering the rise of antibiotic-resistant strains of bacteria, the need for rapid and effective treatments like those developed by Lakewood-Amedex is urgent. Dr. Kelvin Cooper, CEO and Senior Vice President of Research and Development, emphasized the importance of this, saying, "We look forward to accelerating our work targeting this major unmet need."

Nu-3: The Lead Product

Lakewood-Amedex's standout innovation is Nu-3, which is being developed for the topical treatment of mildly infected diabetic foot ulcers (iDFU). Nu-3 utilizes the unique mechanisms of action embedded within the Bisphosphocin® class, allowing it to effectively eliminate a wide range of bacteria, including drug-resistant strains and biofilms. Initial exploratory clinical trials utilizing subclinical doses of Nu-3 have shown promise, indicating no significant safety issues and exhibiting trends of positive antimicrobial responses and improved wound healing.

As part of its commitment to advancing Nu-3, the company plans to launch a Phase 2a clinical trial focusing on safety and dosage, followed by a Phase 2b study designed to evaluate its effectiveness against placebo. The latter will also help determine the best administration regimen for Nu-3 in gel form, making it easier and more effective for patients with mildly infected diabetic foot ulcers to receive treatment.

Forward-looking Statements

It is essential to approach these developments with an understanding of the inherent risks and uncertainties. The statements made regarding the future performance of the company and its products are considered forward-looking and should be interpreted with caution. Lakewood-Amedex has voiced its commitment to transparency and is dedicated to keeping stakeholders informed as it continues to navigate the complexities of biotech innovations.

By joining Nasdaq, Lakewood-Amedex Biotherapeutics is not only enhancing its visibility but also unlocking new financial channels to further its research and development. This listing could indeed signify a turning point, providing encouragement to potential investors and collaborators who believe in the value of innovative biotherapeutics in addressing pressing health concerns.

For more information about Lakewood-Amedex and their biotech advancements, interested parties can visit their official website at lakewoodamedex.com.